Akebia Therapeutics Q1 Earnings Call Highlights

2 hours ago 2

MarketBeat

Thu, May 7, 2026 astatine 8:22 AM CDT 10 min read

Akebia Therapeutics logo

Key Points

Akebia's commercialized motorboat of Vafseo showed beardown momentum with Q1 nett merchandise gross of $15.8 million, ~1,025 prescribers (up ~28% QoQ), astir 7,500 patients (up ~60% sequentially) and ~86% first-refill adherence wherever observed dosing has been adopted.
Company-wide gross fell to $53.5 cardinal arsenic Auryxia income declined, producing a Q1 nett nonaccomplishment of $9.1 cardinal versus a $6.1 cardinal nett a twelvemonth earlier, but currency and equivalents of $162.6 cardinal are expected to money operations for at slightest 2 years.
Pipeline advancement includes near-term readouts (VOCAL by year-end, VOICE successful aboriginal 2027), an ongoing Phase II of praliciguat successful FSGS, a planned Phase II open‑label proceedings of AKB‑097 successful H2 2026, and a Phase I of AKB‑9090 with top-line information expected successful aboriginal 2027.
Interested successful Akebia Therapeutics, Inc.? Here are 5 stocks we similar better.

Akebia Therapeutics Surges connected FDA Approval for Anemia Treatment

Akebia Therapeutics (NASDAQ:AKBA) executives highlighted a “strong start” to 2026 connected the company’s first-quarter net call, pointing to grounds quarterly nett merchandise gross for its anemia cause Vafseo, expanding usage of observed dosing protocols astatine dialysis organizations, and continued advancement crossed a kidney disease-focused improvement pipeline.

Vafseo launch: gross record, prescriber growth, and observed dosing momentum

Chief Executive Officer John Butler said the institution is focused connected 3 priorities: “drive the near-term motorboat show of Vafseo,” proceed gathering grounds to marque it a modular of attraction for dialysis patients, and beforehand its kidney-focused pipeline. In the archetypal quarter, Butler said Vafseo nett merchandise gross was “nearly $16 million,” which the institution described arsenic its highest quarterly Vafseo nett merchandise gross to date.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

Chief Commercial Officer Nick Grund attributed maturation to broader protocol adoption astatine dialysis organizations, peculiarly moves toward observed dosing. “Most dialysis organizations are systematically electing to determination to an observed dosing protocol,” Butler said, adding the displacement could amended adherence and summation utilization implicit time.

Grund reported that astir 1,025 prescribers wrote a Vafseo medicine successful the quarter, astir 28% much than successful the 4th fourth of 2025. He added that astir 30% of those prescribers were from dialysis organizations different than U.S. Renal Care (USRC). From the diligent standpoint, Grund said the fig of patients connected Vafseo astatine quarter-end accrued astir 60% sequentially to “nearly 7,500 patients.” He noted that caller diligent starts successful Q1 were the highest since the archetypal motorboat quarter, with astir caller starts occurring successful March, meaning Q1 gross reflected “at astir lone 1 period of attraction for these patients.”

Read Entire Article